Results 31 to 40 of about 5,633 (190)

Combination of Panax ginseng C. A. Mey and Febuxostat Boasted Cardioprotective Effects Against Doxorubicin-Induced Acute Cardiotoxicity in Rats

Frontiers in Pharmacology, 2022
Doxorubicin (DOX) is an anticancer agent for treating solid and soft tissue malignancies. However, the clinical use of DOX is restricted by cumulative, dose-dependent cardiotoxicity.
Hayder M. Al-Kuraishy, Hany A. Al-Hussaniy, Ali I. Al-Gareeb, Walaa A. Negm, Aya H. El-Kadem, Gaber El-Saber Batiha, Nermeen N. Welson, Gomaa Mostafa-Hedeab, Gomaa Mostafa-Hedeab, Ahmed H Qasem, Carlos Adam Conte-Junior   +10 more
doaj   +1 more source

Comparison between febuxostat and allopurinol uric acid-lowering therapy in patients with chronic heart failure and hyperuricemia: a multicenter randomized controlled trial

Journal of International Medical Research, 2021
Objective Heart failure (HF) is a common and highly morbid cardiovascular disorder. Oxidative stress worsens HF, and uric acid (UA) is a useful oxidative stress marker.
Satoshi Suzuki, Akiomi Yoshihisa, Tetsuro Yokokawa, Atsushi Kobayashi, Takayoshi Yamaki, Hiroyuki Kunii, Kazuhiko Nakazato, Akihiro Tsuda, Tatsunori Tsuda, Toshiyuki Ishibashi, Ichiro Konno, Osamu Yamaguchi, Hirofumi Machii, Naoki Nozaki, Takeshi Niizeki, Takuya Miyamoto, Yasuchika Takeishi,   +17 more
doaj   +1 more source

A Randomized, Double-Blind, Non-Inferiority Study of Febuxostat Versus Allopurinol in Hyperuricemic Chinese Subjects With or Without Gout

Rheumatology and Therapy, 2019
Introduction This 24-week randomized, double-blind, non-inferiority study compared the efficacy and safety of febuxostat, a xanthine oxidase inhibitor, with allopurinol using an up-titration method in hyperuricemic Chinese subjects with or without gout ...
Fengchun Zhang, Zhichun Liu, Lindi Jiang, Hao Zhang, Dongbao Zhao, Yang Li, Hejian Zou, Xiaoyue Wang, Xiangpei Li, Bingyin Shi, Jianhua Xu, Hongjie Yang, Shaoxian Hu, Shen Qu   +13 more
doaj   +1 more source

Long-term inhibition of xanthine oxidase by febuxostat does not decrease blood pressure in deoxycorticosterone acetate (DOCA)-salt hypertensive rats. [PDF]

PLoS ONE, 2013
Xanthine oxidase and its products, uric acid and ROS, have been implicated in the pathogenesis of cardiovascular disease, such as hypertension.
Theodora Szasz, Robert Patrick Davis, Hannah S Garver, Robert J Burnett, Gregory D Fink, Stephanie W Watts   +5 more
doaj   +1 more source

The role of urate and xanthine oxidase in vascular oxidative stress:Future directions [PDF]

, 2009
Vascular oxidative stress has been shown to be a potent factor in the pathophysiology of endothelial dysfunction. Despite current optimal evidence-based therapy, mortality from various cardiovascular disorders remains high.
Allan Struthers, Jacob George, George, Jacob, Struthers, Allan   +3 more
core   +1 more source

Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial.

PLoS Medicine, 2020
BackgroundAn elevated level of serum uric acid (SUA) is associated with an increased risk of cardiovascular disease. Pharmacological intervention with urate-lowering agents, such as the conventional purine analogue xanthine oxidase (XO) inhibitor ...
Atsushi Tanaka, Isao Taguchi, Hiroki Teragawa, Nobukazu Ishizaka, Yumiko Kanzaki, Hirofumi Tomiyama, Masataka Sata, Akira Sezai, Kazuo Eguchi, Toru Kato, Shigeru Toyoda, Ryoichi Ishibashi, Kazuomi Kario, Tomoko Ishizu, Shinichiro Ueda, Koji Maemura, Yukihito Higashi, Hirotsugu Yamada, Mitsuru Ohishi, Kotaro Yokote, Toyoaki Murohara, Jun-Ichi Oyama, Koichi Node, PRIZE study investigators   +23 more
doaj   +1 more source

Febuxostat for Hyperuricemia in Patients with Advanced Chronic Kidney Disease

, 2014
Febuxostat is a nonpurine xanthine oxidase (XO) inhibitor, which recently received marketing approval. However, information regarding the experience with this agent among advanced chronic kidney disease (CKD) patients is limited. In the current study, we
Daisuke Nagata, Osamu Iimura, Tetsu Akimoto, Yuko Watanabe, Chiharu Ito, Eiji Kusano, Sadao Tsunematsu, Yoshiyuki Morishita   +7 more
core   +1 more source

Febuxostat and atrial fibrillation

, 2020
Recently there has been concern that febuxostat may be associated with increased cardiovascular risk than allopurinol,1 leading to a black-box warning by the Federal Drug Administration.
Borghi C, Kuwabara M, Johnson RJ
core   +1 more source

Cardiovascular outcomes of febuxostat and allopurinol: A long-term Taiwanese nationwide cohort study

Journal of the Formosan Medical Association
Introduction: Studies with larger cohorts and longer follow-up periods are required for cardiovascular safety of febuxostat and allopurinol. Material and methods: This population-based, retrospective study was conducted with the Taiwan National Health ...
Tsung-Lin Yang, Hsin-Bang Leu, Shing-Jong Lin, Jiun-Lin Horng, Chun-Ming Shih   +4 more
doaj   +1 more source

Febuxostat ameliorates EAE.

, 2013
Febuxostat (0.75 mg/kg) or vehicle (water) was administered via water bottle from day 10 post-immunization until the end of the study. (A) Mean clinical scores of control mice (filled circle; n = 7) and febuxostat-treated mice (open square; n = 6) after ...
Hideki Mochizuki (204792), Josephe Archie Honorat (443304), Harutoshi Fujimura (178038), Takashi Shirakura (443305), Satoru Tada (439307), Yuji Nakatsuji (339577), Makoto Kinoshita (2566), Kazushiro Takata (339569), Toru Koda (439309), Saburo Sakoda (339576), Tatsusada Okuno (339570)   +10 more
core   +1 more source